A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer

• Published in: The Journal of urology Vol. 155; no. 4; p. 1352
• Main Authors: Debruyne, F M, Dijkman, G A, Lee, D C, Witjes, W P, del Moral, F, Karthaus, H F, van der Mejden, A P, Plasman, J W, Pull, H C, Kums, J J, Idema, J G, Hoefakker, J W, Heijbroek, R P, Kil, P J, Khoe, G S
• Format: Journal Article
• Language: English
• Published: United States 01.04.1996
• Subjects: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal - administration & dosage; Antineoplastic Agents, Hormonal - adverse effects; Delayed-Action Preparations; Goserelin - administration & dosage; Goserelin - adverse effects; Humans; Male; Middle Aged; Prostatic Neoplasms - drug therapy; Testosterone - blood
• ISSN: 0022-5347
• DOI: 10.1016/S0022-5347(01)66264-5

To assess the pharmacodynamic equivalence of the new 10.8 mg. goserelin depot with the current 3.6 mg. depot 3 studies were performed in patients with advanced prostate cancer. In 2 comparative studies 160 patients were randomized for dosing every 12 weeks using the 10.8 mg. depot or every 4 weeks using the 3.6 mg. depot. In the noncomparative study 35 patients received the 10.8 mg. depot. Blood sampling for serum testosterone and evaluation of toxicity was done during the 48-week study period. Serum testosterone profiles of the 10.8 and 3.6 mg. goserlin depots were similar with testosterone levels decreasing into the castrate range by day 21 after depot administration. The safety profile of 10.8 mg. goserelin is comparable to that of the current monthly depot with the main side effects related to androgen deprivation. The new long acting depot was pharmacologically equivalent, and well tolerated locally and systemically, and will offer added convenience to patients and health care personnel.